thumb
July 29, 2021

Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN240)

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following  18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at  2021 Alzheimer’s Association International Conference (AAIC)   Eisai Co., Ltd.

thumb
February 4, 2021

Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the commencement of an offer to purchase for cash (the “Cash Offer”) any and all of its outstanding 5.200% Senior Notes due 2045 (the “Notes”), totaling $1.75 billion in aggregate principal

thumb
February 4, 2021

Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain Investors

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the commencement of a private offer to exchange (the “Exchange Offer”) any and all of its outstanding 5.200% Senior Notes due 2045 (the “Old Notes”), totaling $1.75 billion in aggregate

thumb
February 1, 2021

Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis

Intramuscular injection PLEGRIDY (peginterferon beta-1a) is now approved in the U.S. and the European Union, offering individuals with relapsing multiple sclerosis (MS) a treatment option with significantly reduced injection site reactions PLEGRIDY has a well-characterized safety and efficacy

thumb
January 29, 2021

Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab

The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is June 7, 2021 CAMBRIDGE, Mass. and TOKYO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has extended the review

thumb
January 13, 2021

Biogen to Report Fourth Quarter and Full Year 2020 Financial Results February 3, 2021

Cambridge, Mass. — Biogen Inc. (Nasdaq:BIIB) today announced it will report fourth quarter and full year 2020 financial results Wednesday, February 3, 2021, before the financial markets open.  Following the release of the financials, the Company will host a live webcast with Biogen management at

thumb
January 11, 2021

Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone

The study aims to identify digital biomarkers to help monitor cognitive performance and health including potentially detecting mild cognitive impairment, an early indicator of certain forms of dementia such as Alzheimer’s disease  Cognitive health — the ability to think clearly, to learn and to

thumb
January 8, 2021

Biogen to Participate in Webinar with Alzheimer's Disease International on January 14, 2021

Cambridge, Mass. – Biogen (Nasdaq: BIIB) today announced it will participate in a webinar with Alzheimer’s Disease International (ADI) including a presentation related to its Alzheimer’s disease investigational therapy, aducanumab, as well as a live question and answer (Q&A) session.

thumb
January 8, 2021

Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)

The global Phase 4 RESPOND study will evaluate the efficacy and safety of SPINRAZA in patients with a suboptimal clinical response to Zolgensma Clinical and real-world experience have reported that some patients previously treated with Zolgensma have also been treated with SPINRAZA 1,2,3,4 Biogen

thumb
January 4, 2021

Biogen to Present at the 39th Annual J.P. Morgan Healthcare Conference

Cambridge, MA, - - Biogen Inc .  (Nasdaq: BIIB) announced today that it will present at the virtual 39th Annual J.P. Morgan Healthcare Conference. The webcast will be live on Monday, January 11, 2021 at 10:00 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at

thumb
December 21, 2020

The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis

PLEGRIDY is now approved in the European Union for intramuscular injection, offering individuals with relapsing multiple sclerosis (MS) a differentiated, reliable treatment option combining safety and efficacy to help optimize their treatment experience with significantly reduced injection site